<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369586</url>
  </required_header>
  <id_info>
    <org_study_id>MPZ-I-01</org_study_id>
    <nct_id>NCT04369586</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Trial of Meplazumab in Healthy Volunteer</brief_title>
  <official_title>A Single Center, Double-blinded, ,Placebo-controlled Phase I Clinical Trial in Healthy Volunteer to Evaluate Tolerance and Pharmacokinetics of Meplazumab of Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, double-blinded, placebo-controlled phase I clinical trail in healthy
      volunteer of meplazumab for injection. The primary objective of this phase I trial is to
      evaluate the safety, tolerability, pharmacokinetic characteristics and occupancy
      characteristics of peripheral blood cell receptors of meplazumab in healthy volunteer, and
      provide a reference for the dosage of meplazumab in phase II clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 25, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>0-28 days</time_frame>
    <description>Nature, incidence, and severity of AEs/SAEs, and the relationship to meplazumab treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments of meplazumab- AUC0-tn</measure>
    <time_frame>0-28 days</time_frame>
    <description>AUC0-tn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments of meplazumab- AUC0-∞</measure>
    <time_frame>0-28 days</time_frame>
    <description>AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments of meplazumab-half life time</measure>
    <time_frame>0-28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments of meplazumab-Cmax</measure>
    <time_frame>0-28 days</time_frame>
    <description>Maximum observed plasma concentration of meplazumab (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>meplazumab dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.06mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.12mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.42mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.56mg/kg for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meplazumab multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3mg/kg for double doses, 1 dose/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meplazumab for injection</intervention_name>
    <description>single dose: 6 dose level, multiple dose: 0.3mg/kg/dose</description>
    <arm_group_label>meplazumab dose 1</arm_group_label>
    <arm_group_label>meplazumab dose 2</arm_group_label>
    <arm_group_label>meplazumab dose 3</arm_group_label>
    <arm_group_label>meplazumab dose 4</arm_group_label>
    <arm_group_label>meplazumab dose 5</arm_group_label>
    <arm_group_label>meplazumab dose 6</arm_group_label>
    <arm_group_label>meplazumab multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>meplazumab dose 1</arm_group_label>
    <arm_group_label>meplazumab dose 2</arm_group_label>
    <arm_group_label>meplazumab dose 3</arm_group_label>
    <arm_group_label>meplazumab dose 4</arm_group_label>
    <arm_group_label>meplazumab dose 5</arm_group_label>
    <arm_group_label>meplazumab dose 6</arm_group_label>
    <arm_group_label>meplazumab multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18≤age≤50 years, males or females;

          -  body weight ≥50 kg, body mass index (BMI) should be within 19.0 and 24.0 (both ends
             included),

          -  Vital signs, physical examination, laboratory examination (blood routine, urine
             routine, blood biochemical, coagulation, etc.) and electrocardiogram are within the
             normal range, or beyond the normal range, but the researchers determined that the
             abnormality has no clinical significance (NCS).

          -  No bad habits, including tobacco addiction (&gt;5 cigarettes per day) or drink addiction
             (&gt;15 g of alcohol in a day, and more than two days a week for female, or &gt;25 g in a
             day, and more than two days a week for male; 15 g of alcohol is equivalent to 450 mL
             beer, 150 mL wine or 50 mL light liquor), no history of drug abuse (defined as the use
             of illegal drugs);

          -  No birth plan during the study and within 6 months of completing the test and are
             willing to use non-hormonal contraceptive measures;

          -  Have the ability to communicate normally with medical staff and comply with relevant
             hospital management regulations;

          -  Understand the study and be willing to participate in the study, and sign an informed
             consent form. Incompetent subjects, willing and able to comply with all trial
             requirements.

        Exclusion Criteria:

          -  History of allergies to drugs, food, protein or specific allergies (asthma, rubella,
             eczema dermatitis, etc.);

          -  Vital signs, physical examination, routine laboratory tests (blood routine, urine
             routine, blood biochemistry, coagulation, etc.), 12-lead ECG and other abnormalities
             and clinical significance;

          -  Positive for SARS-CoV-2 specific IgM and IgG antibodies test;

          -  Fever within 3 days before medication (body temperature ≥38.0 ℃);

          -  Pregnant or lactating women;

          -  Have received or are participating in other clinical trials within 3 months before the
             screening;

          -  Be diagnosed or suspected to have immunodeficiency or autoimmune diseases; undergo
             immunosuppressive therapy such as anticancer chemotherapy or radiotherapy before the
             trial, or have received systemic corticosteroid treatment within the past 6 months;

          -  With a history of acupuncture syncope reaction;

          -  Positive for HBV surface antigen, anti-HCV antibody, anti-HIV antibody, and syphilis
             antibody test;

          -  Tobacco addiction (&gt;5 cigarettes per day) or drink addiction (&gt;15 g of alcohol in a
             day, and more than two days a week for female, or &gt;25 g in a day, and more than two
             days a week for male; 15 g of alcohol is equivalent to 450 mL beer, 150 mL wine or 50
             mL light liquor), or can not stop smoking and drinking during the study;

          -  Participated in blood donation or blood loss ≥400mL within 3 months before screening;

          -  Patients not suitable to participate in this study by the judgment of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hospital of the Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Zhe, Dr</last_name>
      <phone>+86-029-84771581</phone>
      <email>zhuping@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ai-Dong Wen, Dr</last_name>
      <phone>+86-029-84773636</phone>
      <email>adwen@fmmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

